ARC-101

N/A

Report date: 2026/03/19 17:12:26

Base Information

Drug NameARC-101
Drug Alias NameARC101ARC-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CLDN6T cell surface glycoprotein CD3 modulators
TargetsClaudin 6T cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsLung Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThird Arc Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesThird Arc Bio Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursEndometrial NeoplasmsLung Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A